NCT05465993View on ClinicalTrials.gov

the Optimal Surveillance Frequency for Stage II/III Gastric Cancer

CompletedOBSERVATIONAL
Enrollment

2,311

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

July 15, 2022

Conditions
Gastric Cancer
Trial Locations (1)

Unknown

Department of Gastric Surgery, Fuzhou

All Listed Sponsors
lead

Fujian Medical University

OTHER

NCT05465993 - the Optimal Surveillance Frequency for Stage II/III Gastric Cancer | Biotech Hunter | Biotech Hunter